| For: | Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013; 5(7): 345-352 [PMID: 23898367 DOI: 10.4254/wjh.v5.i7.345] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v5/i7/345.htm |
| Number | Citing Articles |
| 1 |
Seunghyun Lee, Jung Hoon Kim, Jae Hwan Lee, Jeong Hwa Lee, Joon Koo Han. Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging. European Radiology 2018; 28(1) doi: 10.1007/s00330-017-4960-3
|
| 2 |
Dizhong Chen, Chang Kai Soh, Wei Huang Goh, Haishan Wang. Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma. Journal of Medicinal Chemistry 2018; 61(4) doi: 10.1021/acs.jmedchem.7b01465
|
| 3 |
Wei Chen, Weikai Xiao, Kunsong Zhang, Xiaoyu Yin, Jiaming Lai, Lijian Liang, Dong Chen. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence. Scientific Reports 2016; 6(1) doi: 10.1038/srep22976
|
| 4 |
Jimin Dai, Qichao Huang, Kunwei Niu, Bo Wang, Yijie Li, Chen Dai, Zhinan Chen, Kaishan Tao, Jingyao Dai. Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma. Cancer Medicine 2018; 7(11) doi: 10.1002/cam4.1826
|
| 5 |
Lei Fan, Xiang Huang, Jing Chen, Kai Zhang, Yan-hong Gu, Jing Sun, Shi-yun Cui. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma. Molecular Cancer Therapeutics 2020; 19(5) doi: 10.1158/1535-7163.MCT-19-0203
|
| 6 |
Yuexiang Niu, Gongen Tang, Xiuli Wu, Chaoyu Wu. LncRNA NEAT1 modulates sorafenib resistance in hepatocellular carcinoma through regulating the miR-149-5p/AKT1 axis. Saudi Journal of Gastroenterology 2020; 26(4) doi: 10.4103/sjg.SJG_4_20
|
| 7 |
Fangfang Duan, Hao Wu, Dongwei Jia, Weicheng Wu, Shifang Ren, Lan Wang, Shushu Song, Xinying Guo, Fenglin Liu, Yuanyuan Ruan, Jianxin Gu. O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis. Journal of Hepatology 2018; 68(6) doi: 10.1016/j.jhep.2018.02.003
|
| 8 |
Jiuwei Zhang, Yaodong Chen, Jing Lin, Ruimei Jia, Tingting An, Tianxiu Dong, Yu Zhang, Xiuhua Yang.
Cyclovirobuxine D Exerts Anticancer Effects by Suppressing the
EGFR-FAK-AKT/ERK1/2-Slug
Signaling Pathway in Human Hepatocellular Carcinoma
. DNA and Cell Biology 2020; 39(3) doi: 10.1089/dna.2019.4990
|
| 9 |
Xueying Ren, Yanchun Li, Yi Zhou, Wanye Hu, Chen Yang, Qiangan Jing, Chaoting Zhou, Xu Wang, Jiayu Hu, Luyang Wang, Jing Yang, Hairui Wang, Haifeng Xu, Huanjuan Li, Xiangmin Tong, Ying Wang, Jing Du. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis. Redox Biology 2021; 46 doi: 10.1016/j.redox.2021.102122
|
| 10 |
Aastha Jindal, Anusha Thadi, Kunwar Shailubhai. Hepatocellular Carcinoma: Etiology and Current and Future Drugs. Journal of Clinical and Experimental Hepatology 2019; 9(2) doi: 10.1016/j.jceh.2019.01.004
|
| 11 |
MINORU TOMIZAWA, FUMINOBU SHINOZAKI, YASUFUMI MOTOYOSHI, TAKAO SUGIYAMA, SHIGENORI YAMAMOTO, MAKOTO SUEISHI. Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells. Oncology Letters 2014; 8(5) doi: 10.3892/ol.2014.2484
|
| 12 |
Danyu Du, Chan Liu, Mengyao Qin, Xiao Zhang, Tao Xi, Shengtao Yuan, Haiping Hao, Jing Xiong. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharmaceutica Sinica B 2022; 12(2) doi: 10.1016/j.apsb.2021.09.019
|
| 13 |
Bo Zhai, Fengli Hu, Haijiang Yan, Dali Zhao, Xin Jin, Taishi Fang, Shangha Pan, Xueying Sun, Lishan Xu, Yu-Jia Chang. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress. PLOS ONE 2015; 10(9) doi: 10.1371/journal.pone.0138485
|
| 14 |
Maurice Michel, Marcus Hollenbach, Sabine Pohl, Cristina Ripoll, Alexander Zipprich. Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00785
|
| 15 |
Yong‐Syuan Chen, Chien‐Hsing Lee, Yi‐Hsien Hsieh, Hui‐Ling Chiou, Ming‐Chun Hung, Hsiang‐Lin Lee. Sorafenib, a Tyrosine Kinase Inhibitor, Synergistically Enhances the Ferroptosis Effects of Asiatic Acid in Hepatocellular Carcinoma Cells. Environmental Toxicology 2025; 40(1) doi: 10.1002/tox.24415
|
| 16 |
Yijie Su, Sirui Huang, Yang Duan, Liang Zhang, Shengyun Feng, Yingge Lv, Bei Lan, Chenghao Xuan. ATF7IP inhibits Sorafenib-induced ferroptosis in hepatocellular carcinoma cells by inhibiting CYB5R2 transcription and stabilizing PARK7 protein. Redox Biology 2025; 85 doi: 10.1016/j.redox.2025.103786
|
| 17 |
Kija Malale, Jili Fu, Liewang Qiu, Ke Zhan, Xiuni Gan, Zhechuan Mei. <p>Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway</p>. Cancer Management and Research 2020; doi: 10.2147/CMAR.S243918
|
| 18 |
Alexandru Șandor, Ionel Fizeșan, Ioana Ionuț, Gabriel Marc, Cristina Moldovan, Ilioara Oniga, Adrian Pîrnău, Laurian Vlase, Andreea-Elena Petru, Ioana Macasoi, Ovidiu Oniga. Discovery of A Novel Series of Quinazoline–Thiazole Hybrids as Potential Antiproliferative and Anti-Angiogenic Agents. Biomolecules 2024; 14(2) doi: 10.3390/biom14020218
|
| 19 |
V. Schinzari, V. Barnaba, S. Piconese. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clinical Microbiology and Infection 2015; 21(11) doi: 10.1016/j.cmi.2015.06.026
|
| 20 |
Bao Chen Yang, Po Sing Leung. Irisin Is a Positive Regulator for Ferroptosis in Pancreatic Cancer. Molecular Therapy - Oncolytics 2020; 18 doi: 10.1016/j.omto.2020.08.002
|
| 21 |
Yomna Elleithi, Amal El-Gayar, Mohamed N. Amin. Autophagy modulation attenuates sorafenib resistance in HCC induced in rats. Cell Death & Disease 2024; 15(8) doi: 10.1038/s41419-024-06955-5
|
| 22 |
Gang Hu, Yixin Zhang, Kedong Ouyang, Fubo Xie, Houshun Fang, Xueyang Yang, Kunyan Liu, Zongyu Wang, Xuzhen Tang, Jibin Liu, Lei Yang, Zhenzhou Jiang, Weikang Tao, He Zhou, Luyong Zhang. In�vivo acquired sorafenib‑resistant patient‑derived tumor model displays alternative angiogenic pathways, multi‑drug resistance and chromosome instability. Oncology Letters 2018; doi: 10.3892/ol.2018.9078
|
| 23 |
Ting Liu, Xin Liu, Wenhua Li. Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy. Oncotarget 2016; 7(26) doi: 10.18632/oncotarget.8315
|
| 24 |
Yiming Cheng, Xiaochen Wang, Shuyu Huang, Liang Zhang, Bei Lan, Xuanyuan Li, Hao Chen, Zhenfeng Liu, Yijie Su, Lishan Xi, Shengyun Feng, Yanxuan Guo, Jun Zhou, Yingmei Wang, Chenghao Xuan. A CRISPR-Cas9 library screening identifies CARM1 as a critical inhibitor of ferroptosis in hepatocellular carcinoma cells. Molecular Therapy Nucleic Acids 2023; 34 doi: 10.1016/j.omtn.2023.102063
|
| 25 |
Zheng Wang, Dan Shao, Zhimin Chang, Mengmeng Lu, Yingshuai Wang, Juan Yue, Dian Yang, Mingqiang Li, Qiaobing Xu, Wen-fei Dong. Janus Gold Nanoplatform for Synergetic Chemoradiotherapy and Computed Tomography Imaging of Hepatocellular Carcinoma. ACS Nano 2017; 11(12) doi: 10.1021/acsnano.7b07486
|
| 26 |
Jhen-Yu Chen, Yun-Ju Chen, Chia-Jui Yen, Wen-Shu Chen, Wei-Chien Huang. HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget 2016; 7(1) doi: 10.18632/oncotarget.6337
|
| 27 |
Li Wang, Yaqiong Zhan, Zhe Wu, Mengjia Lin, Xuehang Jin, Lushun Jiang, Yunqing Qiu. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells. Biomedicine & Pharmacotherapy 2020; 125 doi: 10.1016/j.biopha.2020.110033
|
| 28 |
Bo Zhai, Xian Jiang, Changjun He, Dali Zhao, Lixin Ma, Lishan Xu, Hongchi Jiang, Xueying Sun. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Tumor Biology 2015; 36(4) doi: 10.1007/s13277-014-2839-3
|
| 29 |
Wei Dong, Kai Yan, Hua Yu, Lei Huo, Zhihong Xian, Yanqing Zhao, Jutang Li, Yuchan Zhang, Zhenying Cao, Yong Fu, Wenming Cong, Hui Dong. Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Frontiers in Oncology 2021; 10 doi: 10.3389/fonc.2020.605057
|
| 30 |
Su Jong Yu, Jung-Hwan Yoon. Molecular targeted therapy with transarterial chemoembolization. Gastrointestinal Intervention 2013; 2(2) doi: 10.1016/j.gii.2013.09.012
|
| 31 |
Zhiyan Long, Xiangyi Wu, Tianxin Luo, Xiaomei Chen, Jian Huang, Shu Zhang. Exploring the Molecular Mechanism of 1,25(OH)2D3 Reversal of Sorafenib Resistance in Hepatocellular Carcinoma Based on Network Pharmacology and Experimental Validation. Current Issues in Molecular Biology 2025; 47(5) doi: 10.3390/cimb47050319
|
| 32 |
Shiyeol Jun, Soo Young Kim, Seok-Mo Kim, Ki Cheong Park, Hee Jun Kim, Ho Jin Chang, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park. Anti-cancer Activity of Paclitaxel, Lenvatinib and Radiation Combination Therapy on Anaplastic Thyroid Cancer in Vitro and in Vivo. Korean Society for Head and Neck Oncology 2019; 35(2) doi: 10.21593/kjhno/2019.35.2.19
|
| 33 |
Adel H. Jebar, Richard G. Vile, Alan A. Melcher, Stephen Griffin, Peter J. Selby, Fiona Errington-Mais. Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. Journal of General Virology 2015; 96(7) doi: 10.1099/vir.0.000098
|
| 34 |
Fei Long, Chengyong Dong, Keqiu Jiang, Yakun Xu, Xinming Chi, Deguang Sun, Rui Liang, Zhenming Gao, Shujuan Shao, Liming Wang. Melatonin enhances the anti-tumor effect of sorafenib via AKT/p27-mediated cell cycle arrest in hepatocarcinoma cell lines. RSC Advances 2017; 7(34) doi: 10.1039/C7RA02113E
|
| 35 |
Zhengguang Zhang, Cunsi Shen, Fuqiong Zhou. The natural medicinal fungus Huaier promotes the anti-hepatoma efficacy of sorafenib through the mammalian target of rapamycin-mediated autophagic cell death. Medical Oncology 2022; 39(12) doi: 10.1007/s12032-022-01797-7
|
| 36 |
Weidong Jin, Lei Chen, Xun Cai, Yunxiao Zhang, Jianxin Zhang, Dangdang Ma, Xiong Cai, Tao Fu, Zhengping Yu, Fuxiang Yu, Gang Chen. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. Oncology Reports 2017; 37(1) doi: 10.3892/or.2016.5248
|
| 37 |
Jung-Chen Su, Ping-Hui Tseng, Szu-Hsien Wu, Cheng-Yi Hsu, Wei-Tien Tai, Yong-Shi Li, I-Ting Chen, Chun-Yu Liu, Kuen-Feng Chen, Chung-Wai Shiau. SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma. Neoplasia 2014; 16(7) doi: 10.1016/j.neo.2014.06.005
|
| 38 |
Keith I. Block, Charlotte Gyllenhaal, Leroy Lowe, Amedeo Amedei, A.R.M. Ruhul Amin, Amr Amin, Katia Aquilano, Jack Arbiser, Alexandra Arreola, Alla Arzumanyan, S. Salman Ashraf, Asfar S. Azmi, Fabian Benencia, Dipita Bhakta, Alan Bilsland, Anupam Bishayee, Stacy W. Blain, Penny B. Block, Chandra S. Boosani, Thomas E. Carey, Amancio Carnero, Marianeve Carotenuto, Stephanie C. Casey, Mrinmay Chakrabarti, Rupesh Chaturvedi, Georgia Zhuo Chen, Helen Chen, Sophie Chen, Yi Charlie Chen, Beom K. Choi, Maria Rosa Ciriolo, Helen M. Coley, Andrew R. Collins, Marisa Connell, Sarah Crawford, Colleen S. Curran, Charlotta Dabrosin, Giovanna Damia, Santanu Dasgupta, Ralph J. DeBerardinis, William K. Decker, Punita Dhawan, Anna Mae E. Diehl, Jin-Tang Dong, Q. Ping Dou, Janice E. Drew, Eyad Elkord, Bassel El-Rayes, Mark A. Feitelson, Dean W. Felsher, Lynnette R. Ferguson, Carmela Fimognari, Gary L. Firestone, Christian Frezza, Hiromasa Fujii, Mark M. Fuster, Daniele Generali, Alexandros G. Georgakilas, Frank Gieseler, Michael Gilbertson, Michelle F. Green, Brendan Grue, Gunjan Guha, Dorota Halicka, William G. Helferich, Petr Heneberg, Patricia Hentosh, Matthew D. Hirschey, Lorne J. Hofseth, Randall F. Holcombe, Kanya Honoki, Hsue-Yin Hsu, Gloria S. Huang, Lasse D. Jensen, Wen G. Jiang, Lee W. Jones, Phillip A. Karpowicz, W. Nicol Keith, Sid P. Kerkar, Gazala N. Khan, Mahin Khatami, Young H. Ko, Omer Kucuk, Rob J. Kulathinal, Nagi B. Kumar, Byoung S. Kwon, Anne Le, Michael A. Lea, Ho-Young Lee, Terry Lichtor, Liang-Tzung Lin, Jason W. Locasale, Bal L. Lokeshwar, Valter D. Longo, Costas A. Lyssiotis, Karen L. MacKenzie, Meenakshi Malhotra, Maria Marino, Maria L. Martinez-Chantar, Ander Matheu, Christopher Maxwell, Eoin McDonnell, Alan K. Meeker, Mahya Mehrmohamadi, Kapil Mehta, Gregory A. Michelotti, Ramzi M. Mohammad, Sulma I. Mohammed, D. James Morre, Vinayak Muralidhar, Irfana Muqbil, Michael P. Murphy, Ganji Purnachandra Nagaraju, Rita Nahta, Elena Niccolai, Somaira Nowsheen, Carolina Panis, Francesco Pantano, Virginia R. Parslow, Graham Pawelec, Peter L. Pedersen, Brad Poore, Deepak Poudyal, Satya Prakash, Mark Prince, Lizzia Raffaghello, Jeffrey C. Rathmell, W. Kimryn Rathmell, Swapan K. Ray, Jörg Reichrath, Sarallah Rezazadeh, Domenico Ribatti, Luigi Ricciardiello, R. Brooks Robey, Francis Rodier, H.P. Vasantha Rupasinghe, Gian Luigi Russo, Elizabeth P. Ryan, Abbas K. Samadi, Isidro Sanchez-Garcia, Andrew J. Sanders, Daniele Santini, Malancha Sarkar, Tetsuro Sasada, Neeraj K. Saxena, Rodney E. Shackelford, H.M.C. Shantha Kumara, Dipali Sharma, Dong M. Shin, David Sidransky, Markus David Siegelin, Emanuela Signori, Neetu Singh, Sharanya Sivanand, Daniel Sliva, Carl Smythe, Carmela Spagnuolo, Diana M. Stafforini, John Stagg, Pochi R. Subbarayan, Tabetha Sundin, Wamidh H. Talib, Sarah K. Thompson, Phuoc T. Tran, Hendrik Ungefroren, Matthew G. Vander Heiden, Vasundara Venkateswaran, Dass S. Vinay, Panagiotis J. Vlachostergios, Zongwei Wang, Kathryn E. Wellen, Richard L. Whelan, Eddy S. Yang, Huanjie Yang, Xujuan Yang, Paul Yaswen, Clement Yedjou, Xin Yin, Jiyue Zhu, Massimo Zollo. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology 2015; 35 doi: 10.1016/j.semcancer.2015.09.007
|
| 39 |
Jia-Ru Wu, Chi-Tan Hu, Ren-In You, Pei-Ling Ma, Siou-Mei Pan, Ming-Che Lee, Wen-Sheng Wu, Diego Calvisi. Preclinical Trials for Prevention of Tumor Progression of Hepatocellular Carcinoma by LZ-8 Targeting c-Met Dependent and Independent Pathways. PLOS ONE 2015; 10(1) doi: 10.1371/journal.pone.0114495
|
| 40 |
Ting Sun, Wenhao Mao, Hui Peng, Qi Wang, Lin Jiao. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin. Cellular Oncology 2021; 44(3) doi: 10.1007/s13402-021-00595-z
|
| 41 |
Carol Lai-Hung Cheng, Felice Hoi-Ching Tsang, Lai Wei, Mengnuo Chen, Don Wai-Ching Chin, Jialing Shen, Cheuk-Ting Law, Derek Lee, Carmen Chak-Lui Wong, Irene Oi-Lin Ng, Chun-Ming Wong. Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer. Communications Biology 2021; 4(1) doi: 10.1038/s42003-021-02405-6
|
| 42 |
Zhouyang Cheng, Qingfeng Ni, Lei Qin, Yang Shi. MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling. Brazilian Journal of Medical and Biological Research 2021; 54(9) doi: 10.1590/1414-431x2020e10390
|
| 43 |
Wei Meng, Tao Chen. Association between the HGF/c‑MET signaling pathway and tumorigenesis, progression and prognosis of hepatocellular carcinoma (Review). Oncology Reports 2021; 46(3) doi: 10.3892/or.2021.8142
|
| 44 |
Xiangbing Meng, Eric Devor, Shujie Yang, Brandon Schickling, Kimberly Leslie. Role of MTDH, FOXM1 and microRNAs in Drug Resistance in Hepatocellular Carcinoma. Diseases 2014; 2(3) doi: 10.3390/diseases2030209
|
| 45 |
Deniz Cansen Kahraman, Tamer Kahraman, Rengul Cetin-Atalay. Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment. Molecular Cancer Therapeutics 2019; 18(11) doi: 10.1158/1535-7163.MCT-19-0004
|
| 46 |
Lei Zhong, Xiao-Yu Fu, Chan Zou, Ling-Ling Yang, Shu Zhou, Jiao Yang, Yun Tang, Chuan Cheng, Lin-Li Li, Rong Xiang, Li-Juan Chen, Yu-Zong Chen, Yu-Quan Wei, Sheng-Yong Yang. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma. International Journal of Cancer 2014; 135(12) doi: 10.1002/ijc.28944
|
| 47 |
Expression and Function Analysis of Mitotic Checkpoint Genes Identifies TTK as a Potential Therapeutic Target for Human Hepatocellular Carcinoma. PLoS ONE 2014; 9(6) doi: 10.1371/journal.pone.0097739
|
| 48 |
Zhongyan Zhang, Hailiang Wang, Qian Yan, Jinwei Cui, Yubin Chen, Shiye Ruan, Jiayu Yang, Zelong Wu, Mingqian Han, Shanzhou Huang, Qi Zhou, Chuanzhao Zhang, Baohua Hou. Genome-wide CRISPR/Cas9 screening for drug resistance in tumors. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1284610
|
| 49 |
FUHAI WANG, XIAOFENG DONG, PENG XIU, JINGTAO ZHONG, HONGLONG WEI, ZONGZHEN XU, TAO LI, FENG LIU, XUEYING SUN, JIE LI. T7 peptide inhibits angiogenesis via downregulation of angiopoietin-2 and autophagy. Oncology Reports 2015; 33(2) doi: 10.3892/or.2014.3653
|
| 50 |
Mingzhu Tang, Zhe Chen, Di Wu, Linxi Chen. Ferritinophagy/ferroptosis: Iron‐related newcomers in human diseases. Journal of Cellular Physiology 2018; 233(12) doi: 10.1002/jcp.26954
|
| 51 |
Deok Seo, Ji Park, Hee Jung, Min Kang, Byung Kang, Dong Lee, Jae Lee, Seung Yoon, Jeong Jang, Jae Ahn, Pil Sung. Machine learning model reveals roles of interferon‑stimulated genes in sorafenib‑resistant liver cancer. Oncology Letters 2024; 28(3) doi: 10.3892/ol.2024.14571
|
| 52 |
Kai-Wen Chen, Tzu-Ming Ou, Chin-Wen Hsu, Chi-Ting Horng, Ching-Chang Lee, Yuh-Yuan Tsai, Chi-Chang Tsai, Yi-Sheng Liou, Chen-Chieh Yang, Chao-Wen Hsueh, Wu-Hsien Kuo. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World Journal of Hepatology 2015; 7(10): 1412-1420 doi: 10.4254/wjh.v7.i10.1412
|
| 53 |
Carolina Méndez-Blanco, Flavia Fondevila, Andrés García-Palomo, Javier González-Gallego, José L. Mauriz. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Experimental & Molecular Medicine 2018; 50(10) doi: 10.1038/s12276-018-0159-1
|
| 54 |
Kelly Goulart Lima, Gabriele Catyana Krause, Elisa Feller Gonçalves da Silva, Léder Leal Xavier, Léo Anderson Meira Martins, Laura Manzoli Alice, Luiza Bueno da Luz, Rodrigo Benedetti Gassen, Eduardo Cremonese Filippi-Chiela, Gabriela Viegas Haute, Maria Claudia Rosa Garcia, Giselle Afonso Funchal, Leonardo Pedrazza, Camille Kirinus Reghelin, Jarbas Rodrigues de Oliveira. Octyl gallate reduces ATP levels and Ki67 expression leading HepG2 cells to cell cycle arrest and mitochondria-mediated apoptosis. Toxicology in Vitro 2018; 48 doi: 10.1016/j.tiv.2017.12.017
|
| 55 |
Sheng Li, Lina Wu, Hong Zhang, Xijuan Liu, Zilei Wang, Bin Dong, Guang Cao. GINS1 Induced Sorafenib Resistance by Promoting Cancer Stem Properties in Human Hepatocellular Cancer Cells. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.711894
|
| 56 |
Rosa Maria Iacobazzi, Fabio Vischio, Ilaria Arduino, Fabio Canepa, Valentino Laquintana, Maria Notarnicola, Maria Principia Scavo, Giusy Bianco, Elisabetta Fanizza, Angela Assunta Lopedota, Annalisa Cutrignelli, Antonio Lopalco, Amalia Azzariti, Maria Lucia Curri, Massimo Franco, Gianluigi Giannelli, Byung Chul Lee, Nicoletta Depalo, Nunzio Denora. Magnetic implants in vivo guiding sorafenib liver delivery by superparamagnetic solid lipid nanoparticles. Journal of Colloid and Interface Science 2022; 608 doi: 10.1016/j.jcis.2021.09.174
|
| 57 |
Yixiao Sun, Xueran Guan, Ting Zhang, Yue Li, Huiling Shi, Ashleigh Tinotenda Chitakunye, Hanyu Hong, Shihui Zhang, Qin Zhu, Lin Cai. Regulation of the sensitivity of hepatocarcinoma cells by ORMDL3, to sorafenib by autophagy. Medical Oncology 2022; 39(11) doi: 10.1007/s12032-022-01767-z
|
| 58 |
Supritha G. Swamy, Vivek H. Kameshwar, Priya B. Shubha, Chung Yeng Looi, Muthu K. Shanmugam, Frank Arfuso, Arunasalam Dharmarajan, Gautam Sethi, Nanjunda Swamy Shivananju, Anupam Bishayee. Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. Targeted Oncology 2017; 12(1) doi: 10.1007/s11523-016-0452-7
|
| 59 |
Fat-Moon Suk, Chao-Lien Liu, Ming-Hua Hsu, Yu-Ting Chuang, Jack P. Wang, Yi-Jen Liao. Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-53863-2
|
| 60 |
Junhui Sui, Yani Cui, Hanxu Cai, Shaoquan Bian, Zhiyi Xu, Ling Zhou, Yong Sun, Jie Liang, Yujiang Fan, Xingdong Zhang. Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma. Nanoscale 2017; 9(8) doi: 10.1039/C6NR09639E
|
| 61 |
Nikhil Kumar Chourasiya, Firdous Fatima, Mitali Mishra, Shivam Kori, Ratnesh Das, Varsha Kashaw, Arun K. Iyer, Sushil Kumar Kashaw. Structural Insights into N-heterocyclic Moieties as an Anticancer Agent
against Hepatocellular Carcinoma: An Exhaustive Perspective. Mini-Reviews in Medicinal Chemistry 2023; 23(19) doi: 10.2174/1389557523666230508160924
|
| 62 |
Victoria Foy, Mairéad G. McNamara, Juan W. Valle, Angela Lamarca, Julien Edeline, Richard A. Hubner. Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma. Current Oncology 2023; 30(9) doi: 10.3390/curroncol30090628
|
| 63 |
Sónia R. Veiga, Xuemei Ge, Carol A. Mercer, María I. Hernández-Álvarez, Hala Elnakat Thomas, Javier Hernandez-Losa, Santiago Ramón y Cajal, Antonio Zorzano, George Thomas, Sara C. Kozma. Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR. Clinical Cancer Research 2018; 24(15) doi: 10.1158/1078-0432.CCR-18-0177
|
| 64 |
Chen Huang, Yangqian Li, Fengmei Zhang, Chenliang Zhang, Zhenyu Ding. Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma. International Journal of Surgery 2025; 111(4) doi: 10.1097/JS9.0000000000002294
|
| 65 |
Sandeep Kumar Vishwakarma, Priyanka Sharmila, Avinash Bardia, Lakkireddy Chandrakala, N. Raju, G. Sravani, B. V. S. Sastry, Md Aejaz Habeeb, Aleem Ahmed Khan, Marshal Dhayal. Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-08878-y
|
| 66 |
Xue-Mei Jiang, Xiang-Nan Yu, Tao-Tao Liu, Hai-Rong Zhu, Xuan Shi, Enkhnaran Bilegsaikhan, Hong-Ying Guo, Guang-Qi Song, Shu-Qiang Weng, Xiao-Xi Huang, Ling Dong, Harry L.A. Janssen, Xi-Zhong Shen, Ji-Min Zhu. microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma. Biomedicine & Pharmacotherapy 2018; 105 doi: 10.1016/j.biopha.2018.06.097
|
| 67 |
Wei-De Wu, Pin-Shern Chen, Hany A. Omar, El-Shaimaa A. Arafa, Hung-Wei Pan, Jingyueh Jeng, Jui-Hsiang Hung. Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-31209-8
|
| 68 |
Yuanpeng Bao, Song Xu, Junjing Zhou, Chongyong Zhao, Saimin Dai, Yong Zhang, Min Rao. Exosomal miR‐93 derived from hepatocellular carcinoma cell promotes the sorafenib resistance of hepatocellular carcinoma through PTEN/PI3K/Akt pathway. Journal of Biochemical and Molecular Toxicology 2024; 38(3) doi: 10.1002/jbt.23666
|
| 69 |
Hong Xiao, Hangyu Chen, Lei Zhang, Maimaitiyasen Duolikun, Baixin Zhen, Subinuer Kuerban, Xuehui Li, Yuxi Wang, Long Chen, Jian Lin. Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma. World Journal of Surgical Oncology 2024; 22(1) doi: 10.1186/s12957-024-03417-2
|
| 70 |
Yanmin Xu, Huailong Xu, Mingyuan Li, Hua Wu, Yanhe Guo, Jun Chen, Juanjuan Shan, Xuejiao Chen, Junjie Shen, Qinghua Ma, Jingxia Liu, Meiling Wang, Wenxu Zhao, Juan Hong, Yanan Qi, Chao Yao, Qianzhen Zhang, Zhi Yang, Cheng Qian, Jianming Li. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program. Cancer Letters 2019; 454 doi: 10.1016/j.canlet.2019.03.049
|
| 71 |
Hewen Shi, Ying Zou, Xiaoxue Wang, Guoli Wang, Yijia Gao, Fan Yi, junqing Xu, Yancun Yin, Defang Li, Minjing Li. Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma. Discover Oncology 2023; 14(1) doi: 10.1007/s12672-023-00699-y
|
| 72 |
Jingnan Xu, Zhuo Song, Qiujun Guo, Jie Li. Synergistic Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Microenvironment and Cancer Cells. BioMed Research International 2016; 2016 doi: 10.1155/2016/1490738
|
| 73 |
Nichawadee Sandech, Meng Chieh Yang, Pichakorn Juntranggoor, Pattarawit Rukthong, Petr Gorelkin, Nikita Savin, Roman Timoshenko, Alexander Vaneev, Alexander Erofeev, Surasak Wichaiyo, Wisuit Pradidarcheep, Arnatchai Maiuthed. Benja-ummarit induces ferroptosis with cell ballooning feature through ROS and iron-dependent pathway in hepatocellular carcinoma. Journal of Ethnopharmacology 2024; 335 doi: 10.1016/j.jep.2024.118672
|
| 74 |
Hai-Shan Peng, Ming-Bin Liao, Mei-Yin Zhang, Yin Xie, Li Xu, Yao-Jun Zhang, X. F. Steven Zheng, Hui-Yun Wang, Yi-Fei Chen, Stephanie Filleur. Synergistic Inhibitory Effect of Hyperbaric Oxygen Combined with Sorafenib on Hepatoma Cells. PLoS ONE 2014; 9(6) doi: 10.1371/journal.pone.0100814
|
| 75 |
Xuan Wang, Jieyu Ding, Yuanyuan Feng, Lingling Weng, Guangqiang Zhao, Jianfeng Xiang, Minguang Zhang, Dongwei Xing. Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides. Oncology Letters 2017; 13(3) doi: 10.3892/ol.2017.5602
|
| 76 |
Tian-yi Zhou, Lin-han Zhuang, Yan Hu, Yu-lu Zhou, Wen-kai Lin, Dan-dan Wang, Zi-qian Wan, Lin-lin Chang, Ying Chen, Mei-dan Ying, Zi-bo Chen, Song Ye, Jian-shu Lou, Qiao-jun He, Hong Zhu, Bo Yang. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells. Scientific Reports 2016; 6(1) doi: 10.1038/srep30483
|
| 77 |
Zijian Wang, Chunyang Zhou, Yiming Zhang, Xinchen Tian, Haochen Wang, Jibiao Wu, Shulong Jiang. From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma. Biomedicine & Pharmacotherapy 2024; 170 doi: 10.1016/j.biopha.2023.116074
|
| 78 |
Yong Ling, Ji Liu, Jianqiang Qian, Chi Meng, Jing Guo, Weijie Gao, Biao Xiong, Changchun Ling, Yanan Zhang. Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy. Current Medicinal Chemistry 2020; 27(42) doi: 10.2174/0929867327666200102115720
|
| 79 |
Pei-Yi Chu, Shiao-Lin Tung, Kuo-Wang Tsai, Fang-Ping Shen, Shih-Hsuan Chan. Identification of the Novel Oncogenic Role of SAAL1 and Its Therapeutic Potential in Hepatocellular Carcinoma. Cancers 2020; 12(7) doi: 10.3390/cancers12071843
|
| 80 |
FENG LIU, XIAOFENG DONG, HONG LV, PENG XIU, TAO LI, FUHAI WANG, ZONGZHEN XU, JIE LI. Targeting hypoxia-inducible factor-2α enhances sorafenib antitumor activity via β-catenin/C-Myc-dependent pathways in hepatocellular carcinoma. Oncology Letters 2015; 10(2) doi: 10.3892/ol.2015.3315
|
| 81 |
Nian Zhou, Feifei Mao, Shuqun Cheng, Anisha Dsouza. Mechanism Research and Application for Ginsenosides in the Treatment of Hepatocellular Carcinoma. BioMed Research International 2023; 2023(1) doi: 10.1155/2023/7214037
|
| 82 |
Suchita Dattatray Shinde, Neeraj Kulkarni, Bichismita Sahu, Kiran Kalia, Santosh Kumar Behera. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2. 2022; doi: 10.1016/B978-0-323-98807-0.00007-7
|
| 83 |
Xiaofang Sun, Zhanhui Ou, Ruochan Chen, Xiaohua Niu, De Chen, Rui Kang, Daolin Tang. Activation of the p62‐Keap1‐NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 2016; 63(1) doi: 10.1002/hep.28251
|
| 84 |
Yi-Siao Chen, Hsun-Shuo Chang, Hui-Hua Hsiao, Yih-Fung Chen, Yi-Ping Kuo, Feng-Lin Yen, Chia-Hung Yen. Identification of Beilschmiedia tsangii Root Extract as a Liver Cancer Cell–Normal Keratinocyte Dual-Selective NRF2 Regulator. Antioxidants 2021; 10(4) doi: 10.3390/antiox10040544
|
| 85 |
Yenisetti Rajendra Prasad, J. Anakha, Abhay H. Pande. Treating liver cancer through arginine depletion. Drug Discovery Today 2024; 29(4) doi: 10.1016/j.drudis.2024.103940
|
| 86 |
Yu Song, Ming-Qing Wang, Li-Na Yu, Yuan Gao, Jie Bi, Lu-Hui Wang, Fan-Zhi Bu, Zhi-Yong Wu, Yan-Tuan Li. Phenforminium fenbufenate as the first dual-drug molecular salt of phenformin with NSAIDs towards tuning dissolution behavior and enhancing synergic anticancer activity in vitro. Journal of Molecular Structure 2025; 1346 doi: 10.1016/j.molstruc.2025.143252
|
| 87 |
Krittakarn Udomkritayachai, Theeraphat Thiamsuk, Takdanai Jarujamrat, Panaphas Kudikhong, Sira Raksakhom, Phitsamai Suphattana, Natthanan Khankham, Palapoom Thanawong, Supakit Khacha-ananda. Identification of Changes in the Transcriptome Profile of Human Hepatoma HepG2 Cells Exposed to Combined Sorafenib and Cannabis Treatment. International Journal of Molecular Sciences 2026; 27(10) doi: 10.3390/ijms27104342
|
| 88 |
Dizhong Chen, Chang Kai Soh, Wei Huang Goh, Zilong Wang, Haishan Wang. Synthesis and biological evaluation of 6-phenylpurine linked hydroxamates as novel histone deacetylase inhibitors. Bioorganic Chemistry 2020; 98 doi: 10.1016/j.bioorg.2020.103724
|
| 89 |
Ki Cheong Park, Seok-Mo Kim, Jeong Yong Jeon, Bup-Woo Kim, Hyeung Kyoo Kim, Ho Jin Chang, Yong Sang Lee, Soo Young Kim, Seung Hoon Choi, Cheong Soo Park, Hang-Seok Chang. Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer. Neoplasia 2017; 19(3) doi: 10.1016/j.neo.2016.12.005
|
| 90 |
Rui Zhang, Lingchun Kong, Hezhao Zhang, Anhong Zhang, Zhiyong Shi, Pei Wei. Low-Dose Celastrol Modulates IL-6 Secretion to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells. Iranian Journal of Pharmaceutical Research 2025; 24(1) doi: 10.5812/ijpr-160042
|
| 91 |
Xiaoxia Liu, Yanyu Zhang, Wenhua Lu, Yi Han, Jing Yang, Weiye Jiang, Xin You, Yao Luo, Shijun Wen, Yumin Hu, Peng Huang. Mitochondrial TXNRD3 confers drug resistance via redox-mediated mechanism and is a potential therapeutic target in vivo. Redox Biology 2020; 36 doi: 10.1016/j.redox.2020.101652
|
| 92 |
Seunghyun Lee, Jung Hoon Kim, Hyungwon Moon, Hak Jong Lee, Joon Koo Han, Gianfranco D. Alpini. Combined treatment of sorafenib and doxorubicin-loaded microbubble-albumin nanoparticle complex for hepatocellular carcinoma: A feasibility study. PLOS ONE 2020; 15(12) doi: 10.1371/journal.pone.0243815
|
| 93 |
Amanda J. Craig, Ismail Labgaa, Carlos Villacorta-Martin, Massih Ningarhari, Augusto Villanueva. Resistance to Molecular Therapies for Hepatocellular Carcinoma. Resistance to Targeted Anti-Cancer Therapeutics 2017; 13 doi: 10.1007/978-3-319-56197-4_1
|
| 94 |
Jeong-Ju Yoo, Su Jong Yu, Juri Na, Kyungmin Kim, Young Youn Cho, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Hyewon Youn, Jung-Hwan Yoon. Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2019; 20(6) doi: 10.3390/ijms20061292
|
| 95 |
Stefania Moscato, Francesca Ronca, Daniela Campani, Serena Danti. Poly(vinyl alcohol)/gelatin Hydrogels Cultured with HepG2 Cells as a 3D Model of Hepatocellular Carcinoma: A Morphological Study. Journal of Functional Biomaterials 2015; 6(1) doi: 10.3390/jfb6010016
|
| 96 |
Junya Azumi, Toshiaki Tsubota, Tomohiko Sakabe, Goshi Shiota. miR‐181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression. Cancer Science 2016; 107(9) doi: 10.1111/cas.13006
|
| 97 |
Adi Zheng, Nadja Chevalier, Margot Calderoni, Gilles Dubuis, Olivier Dormond, Panos G. Ziros, Gerasimos P. Sykiotis, Christian Widmann. CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma. Oncotarget 2019; 10(66) doi: 10.18632/oncotarget.27361
|
| 98 |
Daniel Kaemmerer, Robin Schindler, Franziska Mußbach, Uta Dahmen, Annelore Altendorf-Hofmann, Olaf Dirsch, Jörg Sänger, Stefan Schulz, Amelie Lupp. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. BMC Cancer 2017; 17(1) doi: 10.1186/s12885-017-3911-3
|
| 99 |
Cristina Quintavalle, Sravanth Kumar Hindupur, Luca Quagliata, Pierlorenzo Pallante, Cecilia Nigro, Gerolama Condorelli, Jesper Bøje Andersen, Katrin Elisabeth Tagscherer, Wilfried Roth, Francesco Beguinot, Markus Hermann Heim, Charlotte Kiu Yan Ng, Salvatore Piscuoglio, Matthias Sebastian Matter. Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib. Cell Death & Disease 2017; 8(10) doi: 10.1038/cddis.2017.512
|
| 100 |
Qiong Zhou, Rui Wang. Emerging trends and knowledge networks in pan-cancer sorafenib resistance: a 20-year bibliometric investigation. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1581820
|
| 101 |
A. Rodríguez-Hernández, E. Navarro-Villarán, R. González, S. Pereira, L.B. Soriano-De Castro, A. Sarrias-Giménez, L. Barrera-Pulido, J.M. Álamo-Martínez, A. Serrablo-Requejo, G. Blanco-Fernández, A. Nogales-Muñoz, A. Gila-Bohórquez, D. Pacheco, M.A. Torres-Nieto, J. Serrano-Díaz-Canedo, G. Suárez-Artacho, C. Bernal-Bellido, L.M. Marín-Gómez, J.A. Barcena, M.A. Gómez-Bravo, C.A. Padilla, F.J. Padillo, J. Muntané. Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells. Redox Biology 2015; 6 doi: 10.1016/j.redox.2015.07.010
|
| 102 |
P-F Zhang, K-S Li, Y-h Shen, P-T Gao, Z-R Dong, J-B Cai, C Zhang, X-Y Huang, M-X Tian, Z-Q Hu, D-M Gao, J Fan, A-W Ke, G-M Shi. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling. Cell Death & Disease 2016; 7(4) doi: 10.1038/cddis.2015.324
|
| 103 |
Bo Zhai, Fengli Hu, Xian Jiang, Jun Xu, Dali Zhao, Bing Liu, Shangha Pan, Xuesong Dong, Gang Tan, Zheng Wei, Haiquan Qiao, Hongchi Jiang, Xueying Sun. Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma. Molecular Cancer Therapeutics 2014; 13(6) doi: 10.1158/1535-7163.MCT-13-1043
|
| 104 |
Nadia Panera, Annalisa Crudele, Ilaria Romito, Daniela Gnani, Anna Alisi. Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2017; 18(1) doi: 10.3390/ijms18010099
|
| 105 |
Lei-Bo Xu, Xiang-De Shi, Wen-Rui Wu, Man-Sheng Zhu, Hong Sun. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. World Journal of Hepatology 2014; 6(12): 830-835 doi: 10.4254/wjh.v6.i12.830
|
| 106 |
Monica A. Kamal, Yasmine M. Mandour, Mostafa K. Abd El-Aziz, Ulrike Stein, Hend M. El Tayebi. Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges. Molecules 2022; 27(17) doi: 10.3390/molecules27175537
|
| 107 |
Umesh Bhanushali, Saranya Rajendran, Keerthana Sarma, Pushkar Kulkarni, Kiranam Chatti, Suvro Chatterjee, C.S. Ramaa. 5-Benzylidene-2,4-thiazolidenedione derivatives: Design, synthesis and evaluation as inhibitors of angiogenesis targeting VEGR-2. Bioorganic Chemistry 2016; 67 doi: 10.1016/j.bioorg.2016.06.006
|
| 108 |
Núria Eritja, Bo-Juen Chen, Ruth Rodríguez-Barrueco, Maria Santacana, Sònia Gatius, August Vidal, Maria Dolores Martí, Jordi Ponce, Laura Bergadà, Andree Yeramian, Mario Encinas, Joan Ribera, Jaume Reventós, Jeff Boyd, Alberto Villanueva, Xavier Matias-Guiu, Xavier Dolcet, David Llobet-Navàs. Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy 2017; 13(3) doi: 10.1080/15548627.2016.1271512
|
| 109 |
Fulei Li, Xiaofei Xue, Mingjun Zheng. Identification and Characterization of an Ageing-Associated 13-lncRNA Signature That Predicts Prognosis and Immunotherapy in Hepatocellular Carcinoma. Journal of Oncology 2023; 2023 doi: 10.1155/2023/4615297
|
| 110 |
Ying-Chi Chen, Wen-Tai Chiu, Chin Chang, Ping-Ching Wu, Ting-Yuan Tu, Hong-Ping Lin, Hsien-Chang Chang. Chemo-photothermal effects of doxorubicin/silica–carbon hollow spheres on liver cancer. RSC Advances 2018; 8(64) doi: 10.1039/C8RA08538B
|
| 111 |
Jian Gao, Yingxue Rong, Yuxing Huang, Peng Shi, Xitao Wang, Xuan Meng, Jiahong Dong, Congying Wu. Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resistance through YAP. Journal of Cellular Physiology 2019; 234(3) doi: 10.1002/jcp.27078
|
| 112 |
Constanze Mittermeier, Andreas Konopa, Susanne Muehlich. Molecular Mechanisms to Target Cellular Senescence in Hepatocellular Carcinoma. Cells 2020; 9(12) doi: 10.3390/cells9122540
|
| 113 |
Li-Hua Liu, Chong-Kai Fang, Fu-Cheng Ge, Ji-Nan Wang, Xiu-Bing Zhang, Rui Luo, Ying Zhang, Kun-Liang Feng, Zhen-Wen Qiu, Chong Zhong, Dong-Hua Yang. JPHYD Inhibits miR-21-5p/Smad7-Mediated Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells. Journal of Oncology 2022; 2022 doi: 10.1155/2022/7823433
|
| 114 |
Mi-Jin Kim, Yeon-Kyung Choi, Soo Young Park, Se Young Jang, Jung Yi Lee, Hye Jin Ham, Byung-Gyu Kim, Hui-Jeon Jeon, Ji-Hyun Kim, Jung-Guk Kim, In-Kyu Lee, Keun-Gyu Park. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC. Molecular Cancer Research 2017; 15(9) doi: 10.1158/1541-7786.MCR-17-0061
|
| 115 |
Maryam Farzaneh, Tariq Masoodi, Farhoodeh Ghaedrahmati, Klaudia Radoszkiewicz, Amir Anbiyaiee, Mohadeseh Sheykhi-Sabzehpoush, Niloofar Khoshdel Rad, Shahab Uddin, Seyedeh Pardis Motiee Jooybari, Seyed Esmaeil Khoshnam, Shirin Azizidoost. An updated review of contribution of long noncoding RNA-NEAT1 to the progression of human cancers. Pathology - Research and Practice 2023; 245 doi: 10.1016/j.prp.2023.154380
|
| 116 |
Giridharan Loghanathan Malarvizhi, Archana Payickattu Retnakumari, Shantikumar Nair, Manzoor Koyakutty. Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma. Nanomedicine: Nanotechnology, Biology and Medicine 2014; 10(8) doi: 10.1016/j.nano.2014.05.011
|
| 117 |
Zeynep Firtina Karagonlar, Dogukan Koc, Evin Iscan, Esra Erdal, Neşe Atabey. Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Science 2016; 107(4) doi: 10.1111/cas.12891
|
| 118 |
Jenny L. Pokorny, Gaspar J. Kitange, Daniel J. Ma. Resistance to Targeted Therapies Against Adult Brain Cancers. Resistance to Targeted Anti-Cancer Therapeutics 2016; doi: 10.1007/978-3-319-46505-0_7
|
| 119 |
Faryal Mehwish Awan, Anam Naz, Ayesha Obaid, Aqsa Ikram, Amjad Ali, Jamil Ahmad, Abdul Khaliq Naveed, Hussnain Ahmed Janjua. MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-11943-1
|
| 120 |
Renato Tassi, Umberto Arena, Roberto Mazzanti. Hepatocellular carcinoma: Where are we?. World Journal of Experimental Medicine 2016; 6(1): 21-36 doi: 10.5493/wjem.v6.i1.21
|
| 121 |
Pei-Pei Hao, Hua Li, Mi-Jin Lee, Yun-Peng Wang, Jong-Hyun Kim, Goung-Ran Yu, Sang-Yeop Lee, Sun-Hee Leem, Kyu-Yun Jang, Dae-Ghon Kim. Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression. Journal of Hepatology 2015; 62(6) doi: 10.1016/j.jhep.2014.12.033
|
| 122 |
Jin Sun Kim, Gwang Hyeon Choi, Yusun Jung, Kang Mo Kim, Se-Jin Jang, Eun Sil Yu, Han Chu Lee. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. Journal of Cancer Research and Clinical Oncology 2018; 144(8) doi: 10.1007/s00432-018-2672-y
|
| 123 |
Lee-Han Kim, Ji-Ae Shin, Boonsil Jang, In-Hyoung Yang, Dong-Hoon Won, Joseph H. Jeong, Tae-Ho Chung, Nam-Pyo Cho, Sung-Dae Cho. Sorafenib potentiates ABT-737-induced apoptosis in human oral cancer cells. Archives of Oral Biology 2017; 73 doi: 10.1016/j.archoralbio.2016.08.034
|
| 124 |
Eunice Y-T Lau, Terence K-W Lee. What are the options for hepatocellular carcinoma patients who progress under sorafenib?. Hepatic Oncology 2016; 3(2) doi: 10.2217/hep-2016-0003
|
| 125 |
Francesca Fornari, Catia Giovannini, Fabio Piscaglia, Laura Gramantieri. Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. Journal of Hepatocellular Carcinoma 2021; doi: 10.2147/JHC.S285726
|
| 126 |
Xing-Chun Gou, Derek Kong, Xu Tang. Contradictory Relationships between Cancer and Normal Cells and Implications for Anti-cancer Therapy. Asian Pacific Journal of Cancer Prevention 2015; 16(13) doi: 10.7314/APJCP.2015.16.13.5143
|
| 127 |
Kelly Goulart Lima, Gabriele Catyana Krause, Aline Daniele Schuster, Anderson Velasque Catarina, Bruno Souza Basso, Fernanda Cristina De Mesquita, Leonardo Pedrazza, Elisa Simon Marczak, Bianca Andrade Martha, Fernanda Bordignon Nunes, Eduardo Cremonese Filippi Chiela, Natália Jaeger, Marcos Paulo Thomé, Gabriela Viegas Haute, Henrique Bregolin Dias, Márcio Vinícius Fagundes Donadio, Jarbas Rodrigues De Oliveira. Gallic acid reduces cell growth by induction of apoptosis and reduction of IL-8 in HepG2 cells. Biomedicine & Pharmacotherapy 2016; 84 doi: 10.1016/j.biopha.2016.10.048
|
| 128 |
Takahiro Kodama, Justin Y. Newberg, Michiko Kodama, Roberto Rangel, Kosuke Yoshihara, Jean C. Tien, Pamela H. Parsons, Hao Wu, Milton J. Finegold, Neal G. Copeland, Nancy A. Jenkins. Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma. Proceedings of the National Academy of Sciences 2016; 113(24) doi: 10.1073/pnas.1606876113
|
| 129 |
Shruthi Kanthaje, Ankita Makol, Anuradha Chakraborti. Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks. Hepatology Research 2018; 48(1) doi: 10.1111/hepr.12991
|
| 130 |
Wenbin Huang, Kunling Chen, Yishi Lu, Donghui Zhang, Yuan Cheng, Liuran Li, Weimei Huang, Guolin He, Hangyu Liao, Lei Cai, Yujun Tang, Liang Zhao, Mingxin Pan. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma. Neoplasia 2021; 23(12) doi: 10.1016/j.neo.2021.11.002
|
| 131 |
Jugang Wu, Hongjuan Chai, Feng Li, Qing Ren, Yan Gu. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma. Life Sciences 2020; 260 doi: 10.1016/j.lfs.2020.118406
|
| 132 |
Jella-Andrea Abraham, Olga Golubnitschaja. Time for Paradigm Change in Management of Hepatocellular Carcinoma: Is a Personalized Approach on the Horizon?. Personalized Medicine 2016; 13(5) doi: 10.2217/pme-2016-0013
|
| 133 |
Soo Young Kim, Seok‐Mo Kim, Hojin Chang, Hang‐Seok Chang, Cheong Soo Park, Yong Sang Lee. Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo. Head & Neck 2020; 42(12) doi: 10.1002/hed.26431
|
| 134 |
Sarita Saraswati, Abdulqader Alhaider, Abdelgalil Mohamed Abdelgadir, Pooja Tanwer, Hesham M. Korashy. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1–mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma. Cell Communication and Signaling 2019; 17(1) doi: 10.1186/s12964-019-0430-7
|
| 135 |
Mingxia Lu, Zhenghua Fei, Ganlu Zhang. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway. Biomedicine & Pharmacotherapy 2018; 97 doi: 10.1016/j.biopha.2017.11.006
|
| 136 |
Tao Bai, Shuai Wang, Yipu Zhao, Rongtao Zhu, Weijie Wang, Yuling Sun. Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications 2017; 491(4) doi: 10.1016/j.bbrc.2017.07.136
|
| 137 |
Lina Ouologuem, Anna Kübler, Sarah Ouologuem, Amar Hadzic, Jan B. Stöckl, Anna Chiara Siciliano, Stefania Forciniti, Salvatore Nigro, Helena Iuele, Valentina Onesto, Anny Nguyen, Dana Matzek, Carla Abrahamian, Christian Grimm, Bastian Popper, Giuseppe Gigli, Loretta L. del Mercato, Olivia M. Merkel, Thomas Fröhlich, Sebastian Theurich, Karin Bartel. Loss of two-pore channel 2 enhances CD8+ T cell cytotoxicity and directly impairs tumour growth via MAPK axis in HCC. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1668066
|
| 138 |
Shu-Xiang Cui, Wen-Na Shi, Zhi-Yu Song, Shu-Qing Wang, Xin-Feng Yu, Zu-Hua Gao, Xian-Jun Qu. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Oncotarget 2016; 7(24) doi: 10.18632/oncotarget.9168
|
| 139 |
Marina Galicia-Moreno, Jorge A Silva-Gomez, Silvia Lucano-Landeros, Arturo Santos, Hugo C Monroy-Ramirez, Juan Armendariz-Borunda, Yu-Chen Fan. Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models. Canadian Journal of Gastroenterology and Hepatology 2021; 2021(1) doi: 10.1155/2021/8837811
|
| 140 |
Weixia Liu, Guodi Wu, Jing Wang, Shanshan Wu, Zhi Chen. Co‑treatment with triptolide and RSL3 induces hepatocellular carcinoma cell apoptosis and ferroptosis. Molecular Medicine Reports 2025; 32(1) doi: 10.3892/mmr.2025.13567
|
| 141 |
Ganga Reddy Velma, Srinivasa Reddy Telukutla, Jayaram Vankudoth, Ajmer Singh Grewal, Steven Privér, Poornachandra Yedla, Ravikumar Akunuri, Donald Wlodkowic, Srihari Pabbaraja, Suresh K. Bhargava, Magdalena Plebanski, Ahmed Kamal. (E)-4-(4-Acrylamidophenoxy)-N-Methylpicolinamides as b-Raf/VEGFR-2 Inhibitors with Antiangiogenic Activity in HUVEC and Zebrafish Model. Molecules 2026; 31(10) doi: 10.3390/molecules31101757
|
| 142 |
Shi-Yan Yan, Yi Zhang, Chao Sun, Hai-Xia Cao, Guang-Ming Li, Yu-Qin Wang, Jian-Gao Fan. The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma. Oncology Letters 2016; 12(2) doi: 10.3892/ol.2016.4694
|
| 143 |
Khadijeh Mahboobnia, Matteo Pirro, Ettore Marini, Francesco Grignani, Evgeny E. Bezsonov, Tannaz Jamialahmadi, Amirhossein Sahebkar. PCSK9 and cancer: Rethinking the link. Biomedicine & Pharmacotherapy 2021; 140 doi: 10.1016/j.biopha.2021.111758
|
| 144 |
Chang-Hao Wu, Xiang Wu, Hong-Wei Zhang. Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor. Journal of Surgical Research 2016; 206(2) doi: 10.1016/j.jss.2016.08.014
|
| 145 |
Shukui Qin, Ying Cheng, Jun Liang, Lin Shen, Yuxian Bai, Jianfeng Li, Jia Fan, Lijian Liang, Yaqi Zhang, Gang Wu, Kun-Ming Rau, Tsai-Shen Yang, Zhixiang Jian, Houjie Liang, Yan Sun. Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study. The Oncologist 2014; 19(11) doi: 10.1634/theoncologist.2014-0190
|
| 146 |
Bin Song, Yu-Jun Shi, Yi Wei, Li Ye Wang, Cai-Wei Yang, Zi-Xing Huang, Qian Li, Qing Xu, Feng Che. Radiomics signature: A potential biomarker for β-arrestin1 phosphorylation prediction in hepatocellular carcinoma. World Journal of Gastroenterology 2022; 28(14): 1479-1493 doi: 10.3748/wjg.v28.i14.1479
|
| 147 |
Dipti Athavale, Surbhi Chouhan, Vimal Pandey, Shyamananda Singh Mayengbam, Snahlata Singh, Manoj Kumar Bhat. Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9). Cancer & Metabolism 2018; 6(1) doi: 10.1186/s40170-018-0187-2
|
| 148 |
Yanli Liu, Jiaye Zhang, Yan Chen, Hasan Sohel, Xinrong Ke, Jingqi Chen, Yin-Xiong Li. The correlation and role analysis of COL4A1 and COL4A2 in hepatocarcinogenesis. Aging 2020; 12(1) doi: 10.18632/aging.102610
|
| 149 |
Amir Sara, Samantha M Ruff, Anne M Noonan, Timothy M Pawlik. Real-World Use of Immunotherapy for Hepatocellular Carcinoma. Pragmatic and Observational Research 2023; doi: 10.2147/POR.S397972
|
| 150 |
Yi Shi, Aimin Huang. Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs. Tumor Biology 2015; 36(11) doi: 10.1007/s13277-015-3565-1
|
| 151 |
Shuang Gao, Qianwen Ni, Xiuli Wu, Tieliu Cao. GHR knockdown enhances the sensitivity of HCC cells to sorafenib. Aging 2020; 12(18) doi: 10.18632/aging.103625
|
| 152 |
David G. Covell, Aritro Nath. A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib. PLOS ONE 2017; 12(8) doi: 10.1371/journal.pone.0181991
|
| 153 |
Jiali Yao, Beifang Ning, Jin Ding. The gut microbiota: an emerging modulator of drug resistance in hepatocellular carcinoma. Gut Microbes 2025; 17(1) doi: 10.1080/19490976.2025.2473504
|
| 154 |
Chi Lv, Shengli Wang, Lin Lin, Chunyu Wang, Kai Zeng, Yiming Meng, Ge Sun, Shan Wei, Yefu Liu, Yue Zhao. USP14 maintains HIF1-α stabilization via its deubiquitination activity in hepatocellular carcinoma. Cell Death & Disease 2021; 12(9) doi: 10.1038/s41419-021-04089-6
|
| 155 |
Dongxu Kang, Zhezhu Han, Geun-Hyeok Oh, Yeonsoo Joo, Hye Jin Choi, Jae J. Song. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib. Yonsei Medical Journal 2017; 58(5) doi: 10.3349/ymj.2017.58.5.899
|
| 156 |
Madhulika Mishra, Priyanka Jayal, Anjali A. Karande, Nagasuma Chandra. Identification of a co‐target for enhancing efficacy of sorafenib in HCC through a quantitative modeling approach. The FEBS Journal 2018; 285(21) doi: 10.1111/febs.14641
|
| 157 |
Jie Zhao, Jinhui Guo, Yanan Wang, Qiancheng Ma, Yu Shi, Feng Cheng, Qiliang Lu, Wen Fu, Guangxiong Ouyang, Ji Zhang, Qiuran Xu, Xiaoge Hu. Research Progress of DUB Enzyme in Hepatocellular Carcinoma. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.920287
|
| 158 |
Néstor Prieto-Domínguez, Carolina Méndez-Blanco, Sara Carbajo-Pescador, Flavia Fondevila, Andrés García-Palomo, Javier González-Gallego, José L. Mauriz. Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated mitophagy. Oncotarget 2017; 8(53) doi: 10.18632/oncotarget.20592
|
| 159 |
Yusra Zarlashat, Shakil Abbas, Abdul Ghaffar. Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy. Cancers 2024; 16(11) doi: 10.3390/cancers16112034
|